Treatment of orthotopic tumor bearing mice with a CD11b agonist (ADH-503) decreased the total number of intratumoral myeloid cells and remaining TAMs exhibited an inflammatory phenotype that promoted intratumoral antigen-specific T cell recruitment and function (103). This evidence concerns the gene ITGAM and neoplasm.